Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Eledon Pharmaceuticals Inc

ELDN ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$3.54

▼ -4.32%

Market Cap $287.66M · Vol 510.86K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$287.66M

Micro Cap

Div Yield

N/A

EPS Growth

-70.00%

YoY

RSI (14)

48.67

Momentum

Beta

0.93

vs Market

52W High

$4.57

22.54% below

52W Low

$1.36

160.29% above

Volume

510.86K

Avg 312.40K

P/B

1.40

Price-to-book

ROE

N/A

Return on equity

Free Float

99.65%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Eledon Pharmaceuticals Inc (ELDN) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ELDN pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-4.07%

-12.59%

-10.38%

+75.25%

YTD

+134.44%

+36.15%

+190.16%

-43.36%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-45,617,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-26.32% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	1.40
P/FCF	N/A
EPS Growth	-70.00%
Outstanding Shares	81.26M

Technical Indicators

50-Day SMA	$3.72
200-Day SMA	$2.92
RSI (14)	48.67
Beta	0.93
52-Week High	$4.57
52-Week Low	$1.36

Volume Today	510.86K
Avg Daily Volume (30D)	312.40K
Relative Volume	1.64x
Volatility (10D)	42.96
Volatility (30D)	56.39
Free Float	99.65%

Analyst Consensus

BUY

Current Price $3.54

Mean Target $9.00

52W Low$1.36 52W High$4.57

Current

Target

$1.36 $4.57

Current Analyst target

+154.24% upside potential · 5 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00241S579

ISINUS28617K1016

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 13, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.